kikmontero Posted - 4 hours ago

$RGNX I have bought more today at $9.17

G101SPM Posted - 1 day ago

$RGNX $9.89 bid. DAC (dollar average cost) (6) $10.45 last $9.69 (11.15.24). EXIT $14.99. UPDATE: * Chardan Capital analyst Daniil Gataulin maintains Regenxbio (RGNX) with a Buy and maintains $52 price target. note: * Chardan Capital doesn't gave a SPM tag rating

Trader2004 Posted - 1 day ago

$RGNX $CRSP $TSHA $NGNE

Brendalikesthestock Posted - 2 days ago

$RGNX bullish 1 hr chart

Hmehtakp Posted - 2 days ago

$RGNX this didn’t age well .. sorry man !!!

wwmeinc Posted - 2 days ago

$TSHA ...An interesting read/article w/Peter Marks over at FDA figuring in the equation...this whole gene sector is being pulled in all directions it seems of late.... $RGNX $TSHA $NGNE ...Even $CRSP is near lows. It is one tough sector for patients for sure and of late,investors/shareholders. Just some thoughts. glta https://www.biopharmadive.com/news/regenxbio-duchenne-gene-therapy-fda-accelerated-approval-results/733156/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202024-11-19%20BioPharma%20Dive%20%5Bissue:67981%5D&utm_term=BioPharma%20Dive

BRITLS Posted - 2 days ago

$RGNX regardless of what we think the market did not like the results. Went down big before the results and still going down

GetThePapersGetThePapers Posted - 2 days ago

$RGNX SRPT > RGNX — you guys are the flintstones vitamins of the industry

GrantDiaz Posted - 2 days ago

$RGNX Buying! I like it from this level.

Stocksrunner Posted - 2 days ago

big shift today in the market for $SRTS $RGNX $HNST $BTMD $VET

lebranjames Posted - 3 days ago

$RGNX absolutely pathetic

Quantumup Posted - 3 days ago

BofA reiterated $SRPT Buy/$210, says Competitor $RGNX DMD gene therapy data still early; Hard to draw conclusion to Elevidys based on small N—Based on KOL✅s doesn't think MDs would hold back on Tx'g given pts get worse over⏲️—est $4.3B in peak Elevidys sales; 60% penetration—📝SRPT also looking to expand to younger pts: $ewtx

WaveRB77 Posted - 3 days ago

$RGNX This company is now pushing the BLA for RGNX 202 until 2026.Call me in 2027 for impact on stock.

WaveRB77 Posted - 3 days ago

$RGNX where is RG314.When are they filing BLA for this drug.Much wider demand.

kikmontero Posted - 3 days ago

$RGNX Don't know why we are n9t flying, but I added today

maphere Posted - 3 days ago

$RGNX Coming up: FDA talks on 314 for PH3 DR this month. $200 million milestone 1Q25, VOUCHER for RGX-121 worth $100,000,000 coming in 2025 BUY and HOLD

ians Posted - 3 days ago

$RGNX Promising functional & biomarker data for RGX-202 gene therapy for Duchenne MD. Looking forward to pivotal trial next. 👍☘️💎 https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-initiates-pivotal-phase-affinity-duchenner-trial-rgx/

topstockalerts Posted - 3 days ago

Pre Market Top Gainers PT2 $ATCH $NIVF $RGNX $PLAG $ZONE

briefingcom Posted - 3 days ago

$RGNX: REGENXBIO initiates AFFINITY DUCHENNE trial of RGX-202; announced new positive efficacy and safety data from the Phase I/II portion of the study; Webcast held at 8:00 a.m. today https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241118070928RGNX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Prosperity_Trades Posted - 3 days ago

Our watchlist this morning: $HCWB $UAVS $VINO $NIVF $RGNX www.prosperitytrades.com

GetVector Posted - 3 days ago

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $NGNE, $RGNX, $TWST.

tradingtwenty Posted - 3 days ago

$RGNX has trended 6 times in the past 24 hours (based on 5 minute intervals). Latest press release on Nov 18, 2024 07:05 AM: REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA Link: https://tradingtwenty.com/news/707177/regenxbio-initiates-pivotal-phase-of-affinity-duchenne-trial-of-rgx-202-gene-therapy-and-reports-positive-functional-data

Rickyrickz70 Posted - 3 days ago

$RGNX very good results... Happy to have bought in on Friday

OpenOutcrier Posted - 3 days ago

$RGNX (+18.5% pre) Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - SI https://ooc.bz/l/48453

SelectiveTrader Posted - 3 days ago

$RGNX in play on positive Duchenne disease trial data. 400m cap at close, 11% short, 10% insider owned, and 90% institutional owned. "Webcast to be held at 8:00 a.m. today" "The initiation of our pivotal trial and newly released positive functional data are exciting milestones on our path to rapidly deliver RGX-202, the only next generation gene therapy in pivotal phase, to the Duchenne community," said Curran M. Simpson President and Chief Executive Officer of REGENXBIO. "The totality of our data demonstrates that RGX-202 provides evidence of improving outcomes for boys with Duchenne and altering the trajectory of this devastating disease, with consistent, robust expression of our novel microdystrophin translating into significant clinical benefit. Based on the strength of the Phase I/II data and our positive discussions and alignment with the FDA, we are quickly advancing RGX-202 toward a BLA filing in 2026 using the accelerated approval pathway." https://finance.yahoo.com/news/regenxbio-initiates-pivotal-phase-affinity-120500075.html

SelectiveTrader Posted - 3 days ago

$RGNX in play on positive data 400m cap at close, 11% short, 10% insider owned, and 90% institutional. "Webcast to be held at 8:00 a.m. today" "The initiation of our pivotal trial and newly released positive functional data are exciting milestones on our path to rapidly deliver RGX-202, the only next generation gene therapy in pivotal phase, to the Duchenne community," said Curran M. Simpson President and Chief Executive Officer of REGENXBIO. "The totality of our data demonstrates that RGX-202 provides evidence of improving outcomes for boys with Duchenne and altering the trajectory of this devastating disease, with consistent, robust expression of our novel microdystrophin translating into significant clinical benefit. Based on the strength of the Phase I/II data and our positive discussions and alignment with the FDA, we are quickly advancing RGX-202 toward a BLA filing in 2026 using the accelerated approval pathway. We continue to evaluate opportunit" https://finance.yahoo.com/news/regenxbio-initiates-pivotal-phase-affinity-120500075.html

briefingcom Posted - 3 days ago

Gapping up: $CYBN +22.3% $RGNX +19.3% $ADVM +14.5% $TWST +14% $TUYA +11.8%

waugusti Posted - 3 days ago

$RGNX best in class. And the only gene therapy for DMD under 4 years old.

frogoracletrading Posted - 3 days ago

$RGNX Support / Resistance Levels Nice move in PM. Here are the levels to watch. No real fun until it gets over 13.02 Larger Image: https://s3.tradingview.com/snapshots/r/RFsUS2wH.png

G101SPM Posted - 3 days ago

$RGNX $11.19 +1.56 bid. DAC (dollar average cost) (6) 10.45 last $9.52 (11.15.24). EXIT $14.99. BRIEF: today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne), has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data. "The initiation of our pivotal trial and newly released positive functional data are exciting milestones on our path to rapidly deliver RGX-202, the only next generation gene therapy in pivotal phase, to the Duchenne community," said Curran M. Simpson President and Chief Executive Officer of REGENXBIO(RGNX).